Spectrum Pharma (SPPI) Prices 21.67M Share Common Offering at $3/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/5/2026
- Dow closes at record on Mideast optimism; SpaceX, AMD drag Nasdaq
- SpaceX tumbles amid AI spending concerns; Musk outlines $1 trillion revenue target
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
- New report warns China transceiver ban would hurt U.S. AI giants
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Opendoor posts Q2 revenue rise as net loss widens year over year
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- Dave & Buster's names CFO Darin Harper as new CEO
- Salesforce president Srini Tallapragada steps down, becomes advisor
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
After-Hours Movers 07/29: (HOME) (APA) (PYPL) Higher; (JAKK) (SPPI) (NOW) Lower (more...)
July 29, 2020 6:14 PM EDTAfter-Hours Stock Movers
At Home Group (NYSE: HOME) 46% HIGHER; reported revenue for the quarter of $515 million versus the consensus estimate of $360.87 million. Comparable store sales increase of approximately 42%.
JAKKS Pacific (NASDAQ: JAKK) 16.7% LOWER; reported Q2 adj. EPS of ($4.38), $0.32 worse than the analyst estimate of ($4.06). Revenue for the quarter came in at $78.8 million versus the consensus estimate of $79.5 million.
Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) 16.4% HIGHER; Spring Bank and F-star Therapeutics,... More
Spectrum Pharma (SPPI) Announces Proposed Public Offering of Common Stock
July 29, 2020 5:22 PM EDTSpectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) (Spectrum), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering. All of the shares in the offering are to be sold by Spectrum. Spectrum also... More
